Search

Your search keyword '"Calza L"' showing total 770 results

Search Constraints

Start Over You searched for: Author "Calza L" Remove constraint Author: "Calza L"
770 results on '"Calza L"'

Search Results

1. Durability, safety, and efficacy of rilpivirine in clinical practice: results from the SCOLTA Project

4. Lipids, weight gain and body mass index in ARV experienced PLWH treated with doravirine-based treatments: a comparison between dual or triple regimens vs bictegravir based triple regimen

5. Trends in mortality in people with HIV from 1999 to 2020: a multi-cohort collaboration

6. Risk of Cardiovascular Events in People with HIV (PWH) Treated with Integrase Strand-Transfer Inhibitors: The Debate Is Not Over; Results of the SCOLTA Study

8. Risk for non-AIDS-defining and AIDS-defining cancer of early versus delayed initiation of antiretroviral therapy

10. Lipids and Transaminase in Antiretroviral-Treatment-Experienced People Living with HIV, Switching to a Doravirine-Based vs. a Rilpivirine-Based Regimen: Data from a Real-Life Setting

11. Metabolic syndrome and body weight in people living with HIV infection: analysis of differences observed in three different cohort studies over a decade

12. Weight Gain: A Possible Side Effect of All Antiretrovirals

13. Efficacy and tolerability of switching to a dual therapy with darunavir/ritonavir plus raltegravir in HIV-infected patients with HIV-1 RNA ≤50 cp/mL

14. Risk for non-AIDS-defining and AIDS-defining cancer of early versus delayed initiation of antiretroviral therapy: A multinational prospective cohort study

15. Burden of Disease in PWH Harboring a Multidrug-Resistant Virus: Data from the PRESTIGIO Registry

17. Burden of Disease in PWH Harboring a Multidrug-Resistant Virus: Data from the PRESTIGIO Registry

18. Growing old with antiretroviral therapy or elderly people in antiretroviral therapy: two different profiles of comorbidity?

19. Invecchiare con la terapia antiretrovirale o essere anziani in terapia antiretrovirale: due profili di comorbidità differenti?

21. Durability of different initial regimens in HIV-infected patients starting antiretroviral therapy with CD4+ counts <200 cells/mm3 and HIV-RNA >5 log10 copies/mL

22. Positioning of darunavir/cobicistat-containing antiretroviral regimens in real life: Results from a large multicentre observational prospective cohort (SCOLTA)

23. Is physician assessment of alcohol consumption useful in predicting risk of severe liver disease among people with HIV and HIV/HCV co-infection?

24. Is physician assessment of alcohol consumption useful in predicting risk of severe liver disease among people with HIV and HIV/HCV co-infection?

25. Positioning of darunavir/cobicistat-containing antiretroviral regimens in real life: results from a large multicentre observational prospective cohort (SCOLTA)

26. Durability of different initial regimens in HIV-infected patients starting antiretroviral therapy with CD4+ counts <200 cells/mm3 and HIV-RNA >5 log10 copies/mL

27. Factors associated with hospital admission for COVID-19 in HIV patients

29. Gender differences in the use of cardiovascular interventions in HIV‐positive persons; the D:A:D Study

32. Fattori associati con il ricovero ospedaliero per COVID-19 in 80 pazienti HIV-positivi italiani. Factors associated with hospital admission for COVID-19 in 80 Italian HIV patients.

33. Durability of Dolutegravir-Based Regimens: A 5-Year Prospective Observational Study

34. Evolution of major non-HIV-related comorbidities in HIV-infected patients in the Italian Cohort of Individuals, Naïve for Antiretrovirals (ICONA) Foundation Study cohort in the period 2004-2014

35. Improvement of lipid profile after switching from efavirenz or ritonavir-boosted protease inhibitors to rilpivirine or once-daily integrase inhibitors: results from a large observational cohort study (SCOLTA)

36. Switching to dual/monotherapy determines an increase in CD8+ in HIV-infected individuals: An observational cohort study

37. Pre-ART HIV-1 DNA in CD4+ T cells correlates with baseline viro-immunological status and outcome in patients under first-line ART

38. Prevalence of acquired resistance mutations in a large cohort of perinatally infected HIV-1 patients

39. Safety and metabolic impact of darunaviur/cobicistat in a real-life setting. Results from the SCOLTA study cohort

40. Factors associated with vitamin D deficiency in HIV-1 infected patients on combination antiretroviral therapy: a case-control study

41. Improvement of lipid profile after switching from efavirenz or ritonavir-boosted protease inhibitors to rilpivirine or once-daily integrase inhibitors: Results from a large observational cohort study (SCOLTA)

42. Switching to dual/monotherapy determines an increase in CD8+ in HIV-infected individuals: An observational cohort study

44. Factors Associated With Weight Gain in People Treated With Dolutegravir

45. Factors associated with hospital admission for COVID-19 in HIV patients

46. Development of C-TILDA: A modified TILDA method for reservoir quantification in long term treated patients infected with subtype C HIV-1

Catalog

Books, media, physical & digital resources